Actinium Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $5.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors highlighting Actinium Pharmaceuticals’ promising developments in targeted radiotherapies. The company has shown significant preclinical success with its ATNM-400 candidate, particularly in non-small cell lung cancer (NSCLC) and prostate cancer. In NSCLC, ATNM-400 demonstrated superior tumor growth inhibition compared to standard treatments, achieving complete tumor regression when combined with Tagrisso. Similarly, in prostate cancer, ATNM-400 outperformed existing therapies, showing enhanced tumor control and survival benefits.
Additionally, Actinium’s innovative approach with ATNM-400, which targets a non-PSMA receptor, positions it as a potentially effective treatment for tumors resistant to current radiotherapeutics. The mechanism of action involves precise targeting and internalization into tumor cells, leading to localized cytotoxicity with minimal off-target effects. These promising preclinical results, along with ongoing progress in other clinical trials, underpin McCarthy’s optimistic outlook and Buy rating for Actinium Pharmaceuticals.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.